Authored By: Sarah
17 Jul 2023

Global Neurological Biomarkers to witness a humongous market growth of USD 6.00 Bn through 2022-2026  

The Global neurological biomarkers are all set to become a billion-dollar industry in making with a revenue growth of USD 6.00 billion and the market's growth momentum will accelerate at a CAGR of 12.43% from 2021 to 2026. 

The neurological biomarkers market can be segmented by indication (AD, PD, ASD, MS, and Others), end-user (hospitals, clinical diagnostic centers, and research organizations and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

Our report captures the growth trajectory of the market and is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking. 

neurological biomarkers market, neurological biomarkers, neurology biomarkers, biomarkers neurology

Neurological Biomarkers Market at a Glance

Navigating through the eccentric business drivers of the Neurological Biomarkers Market has been observed in our analysis of the market landscape

  • Incidences of increasing neurological disorders are primary key drivers of the neurological biomarkers market growth. The neurological disorder includes patients with epilepsy, stroke, Parkinson’s’ disease, and brain tumors.

As per data shared by the Centers for Disease Control and Prevention (CDC), the prevalence of Parkinson's disease increases from 1% to 4% in the aging population of 60 years to 80 years. Similarly, as per The Lancet Global Health Report 2021, the burden of non-communicable neurological disorders is increasing in India mainly due to the aging of the population. Stroke, headache disorders, and epilepsy are the leading contributors to neurological disorders burden in India.

  • The rising focus on accurate neurological diagnostics and the need for better treatment is one of the key neurological biomarkers market trends contributing to the market growth.
  • Vendors are keen on developing clinical trials and R&D of biomarkers, which will be able to identify accurate results for neurological disorders and will drive the demand for neurological biomarkers during the forecast period.

In August 2020, Enigma Biomedical Group (EBG) announced the execution of the development, licensing, and option agreement of two project agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica NV subsidiary of Johnson and Johnson Services, Inc.

Get a comprehensive report summary describing the market landscape of the Neurological Biomarkers Market with all the detailed insights.

Key Companies of the Neurological Biomarkers Market: Some of the key companies doing remarkably well and worth mentioning are Bio Rad Laboratories Inc., Proteome Sciences plc, QIAGEN NV, Thermo Fisher Scientific Inc., Merck KGaA,F. Hoffmann La Roche Ltd., Myriad Genetics Inc.,bioMerieux SA, Charles River Laboratories International Inc., Quest Diagnostics Inc., PerkinElmer Inc., Metabolon Inc., Acrobiosystems Inc., HU Group Holdings Inc.Our report includes qualitative and quantitative analyses of vendors with a wider understanding of the business ecosystem. Order a free sample report today.

Read News Read Less
Interested in this report?
Get your sample now!